U.S. Markets closed

Merck revenue up 8 pct on higher Keytruda sales

April 30 (Reuters) - U.S. drugmaker Merck & Co Inc reported an 8 percent increase in quarterly sales on Tuesday, as sales of its blockbuster lung cancer immunotherapy Keytruda rose.

Merck said net income rose to $2.92 billion, or $1.12 per share, for the first quarter from $736 million, or 27 cents per share, a year earlier.

The company had taken a $1.4 billion charge in the comparable quarter related to a collaboration with Japan's Eisai Co Ltd.

Sales rose to $10.81 billion, above analysts' average estimate of $10.48 billion. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)